Making therapies that make a difference Our clinical and preclinical pipeline includes wholly-owned and partnered therapeutic candidates initially targeting cancers. PIPELINE OF POTENTIAL LEAD PRODUCT CANDIDATES Zanidatamab HER2 x HER2 Bispecific Antibody PIVOTAL ZW49 HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC) PHASE 1 PRECLINICAL & ADVANCED DISCOVERY Antibody Drug Conjugate (ADC) PRECLINICAL T Cell Engaging Bispecifics PRECLINICAL Microenvironment Modulators PRECLINICAL Cytokine Receptor Modulators PRECLINICAL PARTNERSHIPS Bispecific PHASE 1 Bispecific PHASE 1 * XB002 Tissue Factor ADC PHASE 1 JNJ-78278343 (CD3 x KLK2) PHASE 1 Bispecific PRECLINICAL Bispecific PRECLINICAL Bispecific PRECLINICAL Undisclosed PRECLINICAL Bispecific PRECLINICAL Bispecific PRECLINICAL *We entered into a collaboration with Celgene (which is now a Bristol-Myers Squibb company) TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn

Skip to main navigation MENU INVESTOR RELATIONS PRESS RELEASES All Releases Earnings Releases SEARCH YEAR 2021 Date Headline 11/19/2021 Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS) SUMMARY 11/9/2021 Zymeworks Names Neil Josephson, M.D., Chief Medical Officer SUMMARY 11/9/2021 Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA) SUMMARY 11/8/2021 Zymeworks to Present at Upcoming Investor Conferences SUMMARY 11/3/2021 Zymeworks Reports 2021 Third Quarter Financial Results SUMMARY 10/26/2021 Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers SUMMARY 10/5/2021 Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors SUMMARY 9/16/2021 Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress SUMMARY 9/12/2021 Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress SUMMARY 8/4/2021 Zymeworks Reports 2021 Second Quarter Financial Results SUMMARY Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 27 Copyright 2021 , Zymeworks Inc. CLIENT FOOTER LINKS TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info Press Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn